남성 만성 조현병 환자에서 혈중 테스토스테론 농도와 인지 기능의 상관관계 = The Association between Serum Testosterone Level and Cognitive Function in Men with Chronic Schizophrenia

다국어 초록 (Multilingual Abstract)

Objectives：The purpose of this study was to investigate the relationships between sexual hormone level and cognition in male patients with schizophrenia.
Methods：Total 80 male patients with schizophrenia were involved in this study. Among them, 61 patients were classified into normal cognition group(NCG) and 19 patients for lower cognition group(LCG), according to the Korean version of Consortium to Establish a Registry for Alzheimer’s Disease(CERAD-K) and Korean-Color Word Stroop Test. LCG was identified who were included at the below 5 percentile in at least one domain of the cognitive test. All the participants completed Positive and Negative Syndrome Scale(PANSS), Simpson Angus rating Scales(SAS) and Hamilton rating scale for Depression(HAM-D). Sexual hormone levels of prolactin, total testosterone, free-testosterone and estradiol were also checked by blood hormonal assays.
Results：The patients with higher total testosterone level on construction domain were more likely to be included in LCG than NCG. Statistically significant correlations were still observed after adjustment of the several covariants. Total testosterone, free testosterone and estradiol levels have statistically significant positive correlations between each other, but there were negative correlations between prolactin and other hormone levels in 80 male patients with schizophrenia.
Conclusion：These results suggest that sexual hormone may modulate the cognitive deficits in patients with chronic schizophrenia. Sexual hormone levels would be considered as predictive factors about cognitive function of patients with chronic schizophrenia. Furthermore, longitudinal and large-scale control studies would be needed to confirm these results.

목차 (Table of Contents)

• 서론
• 대상 및 방법
• 결과
• 고찰
• 참고문헌

참고문헌 (Reference)

1 이중서, "한국판 양성 및 음성증후군 척도(Positive and Negative Syndrome Scale)의 신뢰도와 타당도" 대한신경정신의학회 40 (40): 1090-1105, 2001

2 이중서, "한국판 Hamilton 우울증 평가 척도의 신뢰도, 타당도 연구" 대한신경정신의학회 44 (44): 456-465, 2005

3 Dunn JF, "Transport of steroid hormones : binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma" 53 : 58-68, 1981

4 Nuechterlein KH, "The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity" 165 : 203-213, 2008

5 Cherrier MM, "Testosterone supplementation improves spatial and verbal memory in healthy older men" 57 : 80-88, 2001

6 Holland J, "Testosterone levels and cognition in elderly men : A review" 69 : 322-337, 2011

7 Shin MS, "Stroop Color and Word Test, a Manual for Clinical and Experimental Uses" Hakjisa 91-, 2007

8 Sherwin BB., "Steroid hormones and cognitive functioning in aging men : a mini-review" 20 : 385-393, 2003

9 Maat A, "Social cognition and quality of life in schizophrenia" 137 : 212-218, 2012

10 Gooren LJ, "Significance of oestrogens in male(patho)physiology" 64 : 126-135, 2003

11 Bicknell RJ, "Sex-steroid action on neurotransmission" 11 : 667-671, 1998

12 Matousek RH, "Sex steroid hormones and cognitive functioning in healthy, older men" 57 : 352-359, 2010

13 Behl C, "Sex hormones, neuroprotection and cognition" 138 : 135-142, 2002

14 Abel KM, "Sex differences in schizophrenia" 22 : 417-428, 2010

15 Moore L, "Serum testosterone levels are related to cognitive function in men with schizophrenia" 38 : 1717-1728, 2013

16 McGrath J, "Schizophrenia: a concise overview of incidence, prevalence, and mortality" 30 : 67-76, 2008

17 Pike CJ, "Protective actions of sex steroid hormones in Alzheimer’s disease" 30 : 239-258, 2009

18 Lee SJ, "Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications" 41 : 569-591, 2001

19 Brann DW, "Neurotrophic and neuroprotective actions of estrogen : Basic mechanisms and clinical implications" 72 : 381-405, 2007

20 Lezak MD, "Neuropsychological assessement" Oxford University Press 1056-, 1995

21 Garcia-Segura LM, "Neuroprotection by estradiol" 63 : 29-60, 2001

22 Petersen RC, "Mild cognitive impairment : clinical characterization and outcome" 56 : 303-308, 1999

23 Gardner DM, "International consensus study of antipsychotic dosing" 167 : 686-693, 2010

24 Lim S, "Increasing Prevalence of Metabolic Syndrome in Korea The Korean National Health and Nutrition Examination Survey for 1998-2007" 34 : 1323-1328, 2011

25 Montalvo I, "Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis" 9 : e89428-, 2014

26 Harvey PD, "Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia" 66 : 101-113, 2004

27 Torner L, "Hyperprolactinemia impairs object recognition without altering spatial learning in male rats" 252 : 32-39, 2013

28 Van Strien JW, "Higher free testosterone level is associated with faster visual processing and more flanker interference in older men" 34 : 546-554, 2009

29 Vermeulen A, "Estradiol in elderly men" 5 : 98-102, 2002

30 Martin DM, "Endogenous testosterone levels, mental rotation performance, and constituent abilities in middle-to-older aged men" 53 : 431-441, 2008

31 Muller M, "Endogenous sex hormone levels and cognitive function in aging men: is there an optimal level?" 64 : 866-871, 2005

32 Halbreich U, "Elevated prolactin levels in patients with schizophrenia : mechanisms and related adverse effects" 28 (28): 53-67, 2003

33 de Bartolomeis A, "Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses" 210 : 387-395, 2013

34 Grundy SM, "Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary" 4 : 198-203, 2005

35 Lee JH, "Development of the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet(CERAD-K): clinical and neuropsychological assessment batteries" 57 : P47-P53, 2002

36 Akhondzadeh S, "Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia" 84 : 405-410, 2006

37 Garrido G, "Computer-assisted cognitive remediation therapy: Cognition, self-esteem and quality of life in schizophrenia" 150 : 563-569, 2013

38 Rathod S, "Cognitive Behavioral Therapy for Schizophrenia" 33 : 527-536, 2010

39 Green MF, "Cognition in schizophrenia: Past, present, and future" 1 : e1-e9, 2014

40 Byerly M, "Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders : recent developments and current perspectives" 27 : 639-661, 2007

41 McKhann G, "Clinical diagnosis of Alzheimer’s disease Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease" 34 : 939-944, 1984

42 Cherrier MM, "Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men" 32 : 72-79, 2007

43 Ko YH, "Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia" 32 : 385-391, 2007

44 Besnard I, "Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance" 40 : 86-94, 2014

45 Simpson GM, "A rating scale for extrapyramidal side effects" 212 : 11-19, 1970